SUPPLEMENT

FY2024 — Five-year review

FY2024PDF · 4 pages120 KB
FIVE-YEAR
REVIEWfor the year ended 30 June 2024

-- 1 of 4 --

Normalised five-year review
R million
Year ended 30 June Compound
growth %	2020 2021 2022 2023* 2024
Statement of financial position – normalised
Total assets 1 894 697 1 870 043 1 999 800* 2 295 274 2 366 815 6
Core lending advances 1 284 131 1 208 468 1 311 441 1 511 037 1 597 898 6
Gross advances before impairments 1 311 095 1 274 052 1 382 058 1 590 447 1 665 706 6
Total impairments 49 380 50 618 47 734 51 072 54 165 2
Advances (net of impairments) 1 261 715 1 223 434 1 334 324 1 539 375 1 611 541 6
Stage 3/NPLs 57 281 60 705 50 886 57 432 67 840 4
Deposits 1 535 015 1 542 078 1 655 972 1 923 103 2 003 151 7
Capital and reserves attributable to equityholders of the group 137 606 151 647 165 642* 181 451 195 664 9
Income statement – normalised
Net interest income before impairment of advances 62 851 64 511 67 856 78 615 86 105 8
Impairment charge (24 383) (13 660) (7 080) (10 949) (12 555) (15)
Total non-interest revenue 42 454 44 980 48 362 52 393 55 295 7
Operational non-interest revenue 42 247 43 548 46 856 51 900 52 873 6
Share of profit of associates and joint ventures after tax 207 1 432 1 506 493 2 422 85
Operating expenses (55 656) (57 342) (61 024) (67 320) (74 405) 8
Earnings attributable to ordinary equityholders of the group 17 265 26 551 32 663 36 634 37 988 22
Key ratios – normalised
ROE (%) 12.9 18.4 20.6 21.1 20.1
ROA (%) 0.96 1.41 1.69 1.71 1.63
Cost-to-income ratio (%) 52.9 52.4 52.5 51.4 52.6
Credit loss ratio (%) – core lending advances 1.97 1.10 0.56 0.78 0.81
Stage 3/NPLs as a % of core lending advances 4.46 5.02 3.88 3.80 4.25
Diversity ratio (%) 40.3 41.1 41.6 40.0 39.1
Share statistics – normalised
Price earnings ratio (times) 12.4 11.3 10.7 10.5 11.4
Price-to-book ratio (times) 1.6 2.0 2.1 2.1 2.2
Market capitalisation 213 497 300 612 349 864 384 250 431 370 19
Closing share price (cents) 3 806 5 359 6 237 6 850 7 690 19
* Restated due to the adoption and retrospective application of IFRS 17.
01
FIRSTRAND GROUP NORMALISED FIVE-YEAR REVIEW

-- 2 of 4 --

Normalised five-year review continued
R million
Year ended 30 June Compound
growth %	2020 2021 2022 2023* 2024
Exchange rates
$/R
– Closing 17.36 14.26 16.41 18.84 18.22
– Average 15.51 15.33 15.19 17.73 18.71
£/R
– Closing 21.43 19.72 19.95 23.95 22.99
– Average 19.57 20.66 20.21 21.31 23.55
Statement of financial position ($ million)** – normalised
Total assets 109 142 131 139 121 865* 121 830 129 902 4
Core lending advances 73 971 84 745 79 917 80 204 87 700 4
Gross advances before impairments 75 524 89 344 84 220 84 419 91 422 5
Total impairments 2 844 3 550 2 909 2 711 2 973 1
Advances (net of impairments) 72 679 85 795 81 312 81 708 88 449 5
Stage 3/NPLs 3 300 4 257 3 101 3 048 3 723 3
Deposits 88 423 108 140 100 912 102 076 109 942 6
Capital and reserves attributable to equityholders of the group 7 927 10 634 10 094* 9 631 10 739 8
Income statement ($ million)# – normalised
Net interest income before impairment of advances 4 052 4 208 4 467 4 434 4 602 3
Impairment charge (1 572) (891) (466) (618) (671) (19)
Total non-interest revenue 2 737 2 934 3 184 2 955 2 955 2
Operational non-interest revenue 2 724 2 841 3 085 2 927 2 826 1
Share of profit of associates and joint ventures after tax 13 93 99 28 129 76
Operating expenses (3 588) (3 741) (4 017) (3 797) (3 977) 3
Earnings attributable to ordinary equityholders of the group 1 113 1 732 2 150 2 066 2 030 16
Statement of financial position (£ million)** – normalised
Total assets 88 413 94 830 100 241* 95 836 102 950 4
Core lending advances 59 922 61 281 65 736 63 091 69 504 4
Gross advances before impairments 61 180 64 607 69 276 66 407 72 454 4
Total impairments 2 304 2 567 2 393 2 132 2 356 1
Advances (net of impairments) 58 876 62 040 66 883 64 275 70 097 4
Stage 3/NPLs 2 673 3 078 2 551 2 398 2 951 3
Deposits 71 629 78 199 83 006 80 297 87 131 5
Capital and reserves attributable to equityholders of the group 6 421 7 690 8 303* 7 576 8 511 7
Income statement (£ million)# – normalised
Net interest income before impairment of advances 3 212 3 123 3 358 3 689 3 656 3
Impairment charge (1 246) (661) (350) (514) (533) (19)
Total non-interest revenue 2 170 2 177 2 393 2 459 2 348 2
Operational non-interest revenue 2 159 2 108 2 318 2 435 2 245 1
Share of profit of associates and joint ventures after tax 11 69 75 23 103 77
Operating expenses (2 844) (2 776) (3 019) (3 159) (3 159) 3
Earnings attributable to ordinary equityholders of the group 882 1 285 1 616 1 719 1 613 16
* Restated due to the adoption and retrospective application of IFRS 17.
** The statement of financial position is converted using the closing rates as disclosed for each reporting year.
# The income statement is converted using the average rate as disclosed for each reporting year.
02
FIRSTRAND GROUP NORMALISED FIVE-YEAR REVIEW

-- 3 of 4 --

www.firstrand.co.za

-- 4 of 4 --